drugset
drugset / Trial / NCT00912691

A Trial of CM-AT in Children With Autism- Open Label Extension Study

NCT00912691 ↗

Phase 3 Completed 165 enrolled Curemark
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether CM-AT is effective in treating the core symptoms of autism.

Timeline

Start
2010-01
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject CM-AT Protein / enzyme biologic — —

Indications

autism